Cargando…

Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality

PURPOSE: Poly(ADP-ribose) polymerase (PARP) inhibitors potentiate radiation therapy in preclinical models of human non-small cell lung cancer (NSCLC) and other types of cancer. However, the mechanisms underlying radiosensitization in vivo are incompletely understood. Herein, we investigated the impa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yanyan, Verbiest, Tom, Devery, Aoife M., Bokobza, Sivan M., Weber, Anika M., Leszczynska, Katarzyna B., Hammond, Ester M., Ryan, Anderson J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Inc 2016
Materias:	Biology Contribution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856738/ https://www.ncbi.nlm.nih.gov/pubmed/27020103 http://dx.doi.org/10.1016/j.ijrobp.2016.01.035

Ejemplares similares

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
por: Bokobza, Sivan M., et al.
Publicado: (2014)

Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer
por: DEVERY, AOIFE M., et al.
Publicado: (2015)

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture
por: Jiang, Yanyan, et al.
Publicado: (2015)

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer
por: Weber, Anika Maria, et al.
Publicado: (2016)

VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells
por: Navarro-Carrasco, Elena, et al.
Publicado: (2021)

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
por: Czyż, Małgorzata, et al.
Publicado: (2016)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
por: Varanda, Ana Beatriz, et al.
Publicado: (2020)

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient‐Derived Xenograft Models
por: Johnston, Michael Edward, et al.
Publicado: (2021)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

NOXA-dependent contextual synthetic lethality of BCL-XL inhibition and “osmotic reprogramming” in colorectal cancer
por: Knoll, Gertrud, et al.
Publicado: (2020)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
por: Bagnolini, Greta, et al.
Publicado: (2020)

Assaults against U.S. law enforcement officers in the line-of-duty: situational context and predictors of lethality
por: Crifasi, Cassandra K., et al.
Publicado: (2016)

Protease Addiction and Synthetic Lethality in Cancer
por: Freije, José M. P., et al.
Publicado: (2011)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015)

ATM activation in hypoxia - causes and consequences
por: Olcina, Monica M, et al.
Publicado: (2014)

Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication
por: Foskolou, Iosifina P., et al.
Publicado: (2017)

Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model
por: Wickstroem, Katrine, et al.
Publicado: (2019)

Hypoxia‐mediated regulation of DDX5 through decreased chromatin accessibility and post‐translational targeting restricts R‐loop accumulation
por: Leszczynska, Katarzyna B., et al.
Publicado: (2023)

Rapid Inhibitor Discovery by Exploiting Synthetic Lethality
por: Muscato, Jacob D., et al.
Publicado: (2022)

Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer
por: Ebeid, Kareem, et al.
Publicado: (2017)

Plasma from human volunteers subjected to remote ischemic preconditioning protects human endothelial cells from hypoxia–induced cell damage
por: Weber, Nina C., et al.
Publicado: (2015)

Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
por: McLellan, Jessica L., et al.
Publicado: (2012)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Protocol for Comprehensive Synthetic Lethality Screens
por: Romero-Moya, Damia, et al.
Publicado: (2020)

The tumor therapy landscape of synthetic lethality
por: Zhang, Biyu, et al.
Publicado: (2021)

Overview of Ferroptosis and Synthetic Lethality Strategies
por: Kinowaki, Yuko, et al.
Publicado: (2021)

Synthetic Lethality Targeting Polθ
por: Drzewiecka, Małgorzata, et al.
Publicado: (2022)

Contextualizing context for synthetic biology – identifying causes of failure of synthetic biological systems
por: Cardinale, Stefano, et al.
Publicado: (2012)

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
por: Fulton, Ben, et al.
Publicado: (2017)

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2017)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

Synthetic lethality between TP53 and ENDOD1
por: Tang, Zizhi, et al.
Publicado: (2022)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Essential Plasticity and Redundancy of Metabolism Unveiled by Synthetic Lethality Analysis
por: Güell, Oriol, et al.
Publicado: (2014)

Synthetic lethal approaches to target cancers with loss of PTEN function
por: Ertay, Ayse, et al.
Publicado: (2023)

Metabolic plasticity in synthetic lethal mutants: Viability at higher cost
por: Massucci, Francesco Alessandro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0l6qs90d2s46kcsg5vjl3nrq6b